Actionnariat et activité des initiés pour Syndax Pharmaceuticals, Inc. (SNDX): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $17.28 |
| Capitalisation | $1.5B |
| Bourse | NASDAQ |
| Pays | US |
Transactions d'Initiés Récentes
| Date | Initié | Type | Actions | Valeur |
|---|---|---|---|---|
| 2026-07-08 | Metzger Michael A | M-Exempt | 32,375 | $207K |
| 2026-07-08 | Metzger Michael A | S-Sale | 32,375 | $785K |
| 2026-07-08 | Metzger Michael A | M-Exempt | 32,375 | $207K |
| 2026-06-11 | Botwood Nicholas A.J. | M-Exempt | 22,515 | $311K |
| 2026-06-12 | Botwood Nicholas A.J. | M-Exempt | 31,235 | $432K |
| 2026-06-11 | Botwood Nicholas A.J. | S-Sale | 34,280 | $617K |
| 2026-06-12 | Botwood Nicholas A.J. | S-Sale | 31,235 | $567K |
| 2026-06-12 | Botwood Nicholas A.J. | M-Exempt | 31,235 | $432K |
| 2026-06-01 | Goldan Keith A. | S-Sale | 1,177 | $22K |
| 2026-06-01 | Metzger Michael A | S-Sale | 6,847 | $130K |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $23.8M | $35.2M | $33.8M | $24.6M | $115.2M | $222.0M | $74.4M | $295.4M | $154.1M | $134.9M |
| Placements à Court Terme | $81.5M | $94.8M | $47.1M | $35.2M | $177.8M | $224.9M | $410.0M | $282.2M | $428.8M | $278.8M |
| Créances | $306000 | $377000 | $253000 | $116000 | $175000 | $429000 | $4.1M | $1.2M | $13.9M | $70.3M |
| Stocks | $2.4M | -$1.4M | $1.1M | 0 | 0 | 0 | 0 | 0 | $366000 | $32.8M |
| Actifs Courants | $108.5M | $133.4M | $83.3M | $62.3M | $298.9M | $448.4M | $489.8M | $580.9M | $603.1M | $528.1M |
| Immobilisations Corporelles | $260000 | $267000 | $373000 | $997000 | $482000 | $1.3M | $1.1M | $1.5M | $2.0M | $1.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $109.0M | $137.2M | $83.9M | $63.5M | $300.6M | $449.7M | $497.2M | $612.9M | $724.8M | $529.7M |
| Dettes Fournisseurs | $2.4M | $2.2M | $1.4M | $6.2M | $3.5M | $5.7M | $4.3M | $10.0M | $11.6M | $16.6M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | $2.3M | 0 | 0 | 0 | $12.1M | 0 |
| Passifs Courants | $10.4M | $15.8M | $16.1M | $18.4M | $18.9M | $20.7M | $29.1M | $58.1M | $103.5M | $120.1M |
| Dette à Long Terme | 0 | 0 | 0 | 0 | $17.8M | $19.9M | 0 | 0 | $331.6M | $345.0M |
| Passifs Totaux | $24.9M | $32.9M | $30.9M | $31.9M | $48.4M | $41.3M | $29.8M | $58.7M | $436.7M | $465.1M |
| Réserves | -$305.3M | -$366.1M | -$439.4M | -$495.5M | -$568.6M | -$543.7M | -$693.0M | -$902.4M | -$1.22B | -$1.51B |
| Capitaux Propres | $84.1M | $104.3M | $53.0M | $31.6M | $252.2M | $408.4M | $467.4M | $554.2M | $288.1M | $64.6M |
| Dette Totale | 0 | 0 | 0 | $897000 | $20.5M | $21.0M | $1.2M | $1.6M | $345.7M | $346.5M |
| Dette Nette | -$105.3M | -$133.2M | -$80.9M | -$58.9M | -$272.5M | -$425.9M | -$483.2M | -$575.9M | -$237.2M | -$67.2M |
| Fonds de Roulement | $98.1M | $117.6M | $67.2M | $44.0M | $280.0M | $427.7M | $460.7M | $522.8M | $499.5M | $408.0M |
Santé financière
| Dette / Capitaux propres | 39.03 |
| Ratio de liquidité | 6.77 |
Rentabilité
| Rentabilité des capitaux propres | -372.94% |
| Rentabilité du capital investi | -32.10% |
| Rentabilité des actifs | -31.37% |
| Marge brute | 97.47% |
| Marge opérationnelle | -77.05% |
| Marge nette | -87.60% |
Entreprises liées: AMLX · ATAI · CVAC · IMTX · INBX · NKTR · ORIC
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de SNDX: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions